» Articles » PMID: 38013618

Cinobufotalin Prevents Bone Loss Induced by Ovariectomy in Mice Through the BMPs/SMAD and Wnt/β-catenin Signaling Pathways

Overview
Date 2023 Nov 28
PMID 38013618
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteoporosis is a chronic bone disease characterized by bone loss and decreased bone strength. However, current anti-resorptive drugs carry a risk of various complications. The deep learning-based efficacy prediction system (DLEPS) is a forecasting tool that can effectively compete in drug screening and prediction based on gene expression changes. This study aimed to explore the protective effect and potential mechanisms of cinobufotalin (CB), a traditional Chinese medicine (TCM), on bone loss.

Methods: DLEPS was employed for screening anti-osteoporotic agents according to gene profile changes in primary osteoporosis. Micro-CT, histological and morphological analysis were applied for the bone protective detection of CB, and the osteogenic differentiation/function in human bone marrow mesenchymal stem cells (hBMMSCs) were also investigated. The underlying mechanism was verified using qRT-PCR, Western blot (WB), immunofluorescence (IF), etc. RESULTS: A safe concentration (0.25 mg/kg in vivo, 0.05 μM in vitro) of CB could effectively preserve bone mass in estrogen deficiency-induced bone loss and promote osteogenic differentiation/function of hBMMSCs. Both BMPs/SMAD and Wnt/β-catenin signaling pathways participated in CB-induced osteogenic differentiation, further regulating the expression of osteogenesis-associated factors, and ultimately promoting osteogenesis.

Conclusion: Our study demonstrated that CB could significantly reverse estrogen deficiency-induced bone loss, further promoting osteogenic differentiation/function of hBMMSCs, with BMPs/SMAD and Wnt/β-catenin signaling pathways involved.

Citing Articles

Cinobufotalin prevents bone loss induced by ovariectomy in mice through the BMPs/SMAD and Wnt/β-catenin signaling pathways.

Lu D, Zeng L, Li Y, Gu R, Hu M, Zhang P Animal Model Exp Med. 2023; 7(3):208-221.

PMID: 38013618 PMC: 11228090. DOI: 10.1002/ame2.12359.

References
1.
Chen B, Harrison R, Papadatos G, Willett P, Wood D, Lewell X . Evaluation of machine-learning methods for ligand-based virtual screening. J Comput Aided Mol Des. 2007; 21(1-3):53-62. DOI: 10.1007/s10822-006-9096-5. View

2.
Xue X, Xue J, Hu W, Shi F, Yang Y . Nomilin targets the Keap1-Nrf2 signalling and ameliorates the development of osteoarthritis. J Cell Mol Med. 2020; 24(15):8579-8588. PMC: 7412705. DOI: 10.1111/jcmm.15484. View

3.
Benisch P, Schilling T, Klein-Hitpass L, Frey S, Seefried L, Raaijmakers N . The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One. 2012; 7(9):e45142. PMC: 3454401. DOI: 10.1371/journal.pone.0045142. View

4.
Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

5.
Guo N, Miao Y, Sun M . Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: a meta-analysis of 27 trials involving 2,079 patients. Onco Targets Ther. 2018; 11:8835-8853. PMC: 6290874. DOI: 10.2147/OTT.S182840. View